New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

about

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis.Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.Idiopathic pulmonary fibrosis: pathogenesis and management.

P2860

Q47658743-792DDF48-630F-41EF-9335-54A771B4ED20 Q49897554-E832062C-3849-49AA-91B3-BEF09AF7C217 Q50326794-8F4F9DA7-EB51-4284-A278-6F4D2E87565E

P2860

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

Item

http://www.wikidata.org/entity/Q39330304

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

@en

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

@nl

type

Item

label

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

@en

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

@nl

prefLabel

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

@en

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

@nl

P1476

New treatment directions for IPF: current status of ongoing and upcoming clinical trials

@en

P2093

Francesco Macagno

http://www.w3.org/2001/XMLSchema#string

Loredana Panico

http://www.w3.org/2001/XMLSchema#string

Ludovica Berardini

http://www.w3.org/2001/XMLSchema#string

Paolo Maria Leone

http://www.w3.org/2001/XMLSchema#string

P2860

Selective ROCK2 inhibition in focal cerebral ischemia

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production

Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix

Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment.

Dasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental Silicosis

GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease

Integrins: bidirectional, allosteric signaling machines

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

P304

533-548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17476348.2017.1335601

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Varone

Luca Richeldi

Pier-Valerio Mari

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28544857

http://www.w3.org/2001/XMLSchema#string

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

about

P2860

P2860

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698